Synthesis and Antitumor Properties of BQC-Glucuronide, a Camptothecin Prodrug for Selective Tumor Activation

Molecular Pharmaceutics

Volumn 13, Issue 4, 2016, Pages 1242-1250

  Prijovich, Zeljko M ^a,e   Burnouf, Pierre Alain ^a,b   Chou, Hua Cheng ^d   Huang, Ping Ting ^a   Chen, Kai Chuan ^a   Cheng, Tian Lu ^c   Leu, Yu Lin ^d   Roffler, Steve R ^a  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^e UNIVERSITY OF PATRAS   (Greece)

Author keywords

ADEPT; albumin influence; beta glucuronidase; camptothecin; cancer; glucuronide; prodrug; targeted therapy

Indexed keywords

5,6 DIHYDRO 4H BENZO[DE]QUINOLINE CAMPTOTHECIN; 5,6 DIHYDRO 4H BENZO[DE]QUINOLINE CAMPTOTHECIN GLUCURONIDE; 9 AMINOCAMPTOTHECIN; BETA GLUCURONIDASE; CAMPTOTHECIN DERIVATIVE; FIRTECAN; HUMAN SERUM ALBUMIN; PRODRUG; TOPOTECAN; UNCLASSIFIED DRUG; 9-AMINOCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; GLUCURONIDE; IRINOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; HYDROLYSIS; IC50; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CELL SURVIVAL; CHEMISTRY; COLONIC NEOPLASMS; DRUG EFFECTS; METABOLISM; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CELL LINE, TUMOR; CELL SURVIVAL; COLONIC NEOPLASMS; FEMALE; GLUCURONIDASE; GLUCURONIDES; HUMANS; MICE; MICE, INBRED BALB C; PRODRUGS; TOPOTECAN;

EID: 84963815837     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.5b00771     Document Type: Article

References (45)

1. Kim, S.; Takahashi, H.; Lin, W. W.; Descargues, P.; Grivennikov, S.; Kim, Y.; Luo, J. L.; Karin, M. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis Nature 2009, 457 (7225) 102 10.1038/nature07623
2. Mantovani, A.; Sica, A.; Allavena, P.; Garlanda, C.; Locati, M. Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation Hum. Immunol. 2009, 70 (5) 325-330 10.1016/j.humimm.2009.02.008
3. Condeelis, J.; Pollard, J. W. Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis Cell 2006, 124 (2) 263-266 10.1016/j.cell.2006.01.007
4. Pollard, J. W. Tumour-educated macrophages promote tumour progression and metastasis Nat. Rev. Cancer 2004, 4 (1) 71 10.1038/nrc1256
5. Schumacher, U.; Adam, E.; Zangemeister-Wittkel, U.; Gossrau, R. Histochemistry of therapeutically relevant enzymes in human tumours transplanted into severe combined immunodeficient (SCID) mice: nitric oxide synthase-associated diaphorase, beta-D-glucuronidase and non-specific alkaline phosphatase Acta Histochem. 1996, 98 (4) 381 10.1016/S0065-1281(96)80004-3
6. Bosslet, K.; Straub, R.; Blumrich, M.; Czech, J.; Gerken, M.; Sperker, B.; Kroemer, H. K.; Gesson, J. P.; Koch, M.; Monneret, C. Elucidation of the mechanism enabling tumor selective prodrug monotherapy Cancer Res. 1998, 58 (6) 1195-201
7. De Palma, M.; Coussens, L. Immune Cells and Inflammatory Mediators as Regulators of Tumor Angiogenesis. In Angiogenesis: An Integrative Approach from Science to Medicine; Figg, W. D.; Folkman, J., Eds.; Springer Science+Business Media, LLC: New York, 2008.
8. Houba, P. H. J.; Boven, E.; van der Meulen-Muileman, I. H.; Leenders, R. G. G.; Scheeren, J. W.; Pinedo, H. M.; Haisma, H. J. Distribution and pharmacokinetics of the prodrug daunorubicin-GA3 in nude mice bearing human ovarian cancer xenografts Biochem. Pharmacol. 1999, 57 (6) 673-680 10.1016/S0006-2952(98)00343-8
9. Juan, T. Y.; Roffler, S. R.; Hou, H. S.; Huang, S. M.; Chen, K. C.; Leu, Y. L.; Prijovich, Z. M.; Yu, C. P.; Wu, C. C.; Sun, G. H.; Cha, T. L. Antiangiogenesis targeting tumor microenvironment synergizes glucuronide prodrug antitumor activity Clin. Cancer Res. 2009, 15 (14) 4600-11 10.1158/1078-0432.CCR-09-0090
10. Komatsu, N.; Waki, M.; Sue, M.; Tokuda, C.; Kasaoka, T.; Nakajima, M.; Higashi, N.; Irimura, T. Heparanase expression in B16 melanoma cells and peripheral blood neutrophils before and after extravasation detected by novel anti-mouse heparanase monoclonal antibodies J. Immunol. Methods 2008, 331 (1-2) 82-93 10.1016/j.jim.2007.11.014
11. Sperker, B.; Werner, U.; Murdter, T. E.; Tekkaya, C.; Fritz, P.; Wacke, R.; Adam, U.; Gerken, M.; Drewelow, B.; Kroemer, H. K. Expression and function of beta-glucuronidase in pancreatic cancer: potential role in drug targeting Naunyn-Schmiedeberg's Arch. Pharmacol. 2000, 362 (2) 110-5 10.1007/s002100000260
12. Rofstad, E. K.; Mathiesen, B.; Kindem, K.; Galappathi, K. Acidic Extracellular pH Promotes Experimental Metastasis of Human Melanoma Cells in Athymic Nude Mice Cancer Res. 2006, 66 (13) 6699-6707 10.1158/0008-5472.CAN-06-0983
13. Sung, S. Y.; Hsieh, C. L.; Wu, D.; Chung, L. W.; Johnstone, P. A. Tumor microenvironment promotes cancer progression, metastasis, and therapeutic resistance Curr. Probl Cancer 2007, 31 (2) 36-100 10.1016/j.currproblcancer.2006.12.002
14. Tannock, I. F.; Rotin, D. Acid pH in tumors and its potential for therapeutic exploitation Cancer Res. 1989, 49 (16) 4373-84
15. Chen, B. M.; Chan, L. Y.; Wang, S. M.; Wu, M. F.; Chern, J. W.; Roffler, S. R. Cure of malignant ascites and generation of protective immunity by monoclonal antibody-targeted activation of a glucuronide prodrug in rats Int. J. Cancer 1997, 73 (3) 392-402 10.1002/(SICI)1097-0215(19971104)73:3<392::AID-IJC14>3.0.CO;2-F
16. Chen, K. C.; Cheng, T. L.; Leu, Y. L.; Prijovich, Z. M.; Chuang, C. H.; Chen, B. M.; Roffler, S. R. Membrane-localized activation of glucuronide prodrugs by beta-glucuronidase enzymes Cancer Gene Ther. 2007, 14 (2) 187-200 10.1038/sj.cgt.7700999
17. Chen, K.-C.; Wu, S.-Y.; Leu, Y.-L.; Prijovich, Z. M.; Chen, B.-M.; Wang, H.-E.; Cheng, T.-L.; Roffler, S. R. A humanized immunoenzyme with enhanced activity for glucuronide prodrug activation in the tumor microenvironment Bioconjugate Chem. 2011, 22 (5) 938-948 10.1021/bc1005784
18. Cheng, C.; Chen, F.; Lu, Y.; Tzou, S.; Wang, J.; Kao, C.; Liao, K.; Cheng, T.; Chuang, C.; Chen, B. Expression of β-glucuronidase on the surface of bacteria enhances activation of glucuronide prodrugs Cancer Gene Ther. 2013, 20 (5) 276-281 10.1038/cgt.2013.17
19. Cheng, C. M.; Lu, Y. L.; Chuang, K. H.; Hung, W. C.; Shiea, J.; Su, Y. C.; Kao, C. H.; Chen, B. M.; Roffler, S.; Cheng, T. L. Tumor-targeting prodrug-activating bacteria for cancer therapy Cancer Gene Ther. 2008, 15, 393 10.1038/cgt.2008.10
20. Cheng, T. L.; Chen, B. M.; Chan, L. Y.; Wu, P. Y.; Chern, J. W.; Roffler, S. R. Poly(ethylene glycol) modification of beta-glucuronidase-antibody conjugates for solid-tumor therapy by targeted activation of glucuronide prodrugs Cancer Immunol. Immunother. 1997, 44 (6) 305-15 10.1007/s002620050387
21. de Graaf, M.; Pinedo, H. M.; Oosterhoff, D.; van der Meulen-Muileman, I. H.; Gerritsen, W. R.; Haisma, H. J.; Boven, E. Pronounced antitumor efficacy by extracellular activation of a doxorubicin-glucuronide prodrug after adenoviral vector-mediated expression of a human antibody-enzyme fusion protein Hum. Gene Ther. 2004, 15 (3) 229-38 10.1089/104303404322886084
22. F. Antunes, I.; Haisma, H. J.; Elsinga, P. H.; Di Gialleonardo, V.; Waarde, A. v.; Willemsen, A. T.; Dierckx, R. A.; de Vries, E. F. Induction of β-glucuronidase release by cytostatic agents in small tumors Mol. Pharmaceutics 2012, 9 (11) 3277-3285 10.1021/mp300327w
23. Fejerskov, B.; Zelikin, A. N. Substrate mediated enzyme prodrug therapy PLoS One 2012, 7, e49619 10.1371/journal.pone.0049619
24. Huang, P.; Chen, K.; Prijovich, Z.; Cheng, T.; Leu, Y.; Roffler, S. Enhancement of CPT-11 antitumor activity by adenovirus-mediated expression of β-glucuronidase in tumors Cancer Gene Ther. 2011, 18 (6) 381-389 10.1038/cgt.2011.3
25. Prijovich, Z. M.; Chen, K. C.; Roffler, S. R. Local enzymatic hydrolysis of an endogenously generated metabolite can enhance CPT-11 anticancer efficacy Mol. Cancer Ther. 2009, 8 (4) 940-6 10.1158/1535-7163.MCT-08-0812
26. Hsiang, Y. H.; Hertzberg, R.; Hecht, S.; Liu, L. F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I J. Biol. Chem. 1985, 260 (27) 14873-14878
27. Burke, T. G.; Munshi, C. B.; Mi, Z.; Jiang, Y. The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs J. Pharm. Sci. 1995, 84 (4) 518-9 10.1002/jps.2600840426
28. Mi, Z.; Malak, H.; Burke, T. G. Reduced albumin binding promotes the stability and activity of topotecan in human blood Biochemistry 1995, 34 (42) 13722-8 10.1021/bi00042a002
29. Houba, P. H.; Boven, E.; van der Meulen-Muileman, I. H.; Leenders, R. G.; Scheeren, J. W.; Pinedo, H. M.; Haisma, H. J. A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer Br. J. Cancer 2001, 84 (4) 550-7 10.1054/bjoc.2000.1640
30. Prijovich, Z. M.; Chen, B. M.; Leu, Y. L.; Chern, J. W.; Roffler, S. R. Anti-tumour activity and toxicity of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in mice Br. J. Cancer 2002, 86 (10) 1634-8 10.1038/sj.bjc.6600317
31. Leu, Y. L.; Roffler, S. R.; Chern, J. W. Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT) J. Med. Chem. 1999, 42 (18) 3623-8 10.1021/jm990124q
32. Burke, T. G.; Mi, Z. The structural basis of camptothecin interactions with human serum albumin: impact on drug stability J. Med. Chem. 1994, 37 (1) 40-6 10.1021/jm00027a005
33. Prijovich, Z. M.; Leu, Y. L.; Roffler, S. R. Stability of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in the presence of human serum albumin Biochem. Pharmacol. 2003, 66 (7) 1181-7 10.1016/S0006-2952(03)00472-6
34. Prijovich, Z. M.; Leu, Y.-L.; Roffler, S. R. Effect of pH and human serum albumin on the cytotoxicity of a glucuronide prodrug of 9-aminocamptothecin Cancer Chemother. Pharmacol. 2007, 60 (1) 7-17 10.1007/s00280-006-0340-4
35. Sugimori, M.; Ejima, A.; Ohsuki, S.; Uoto, K.; Mitsui, I.; Kawato, Y.; Hirota, Y.; Sato, K.; Terasawa, H. Synthesis and antitumor activity of ring A- and F-modified hexacyclic camptothecin analogues J. Med. Chem. 1998, 41 (13) 2308-18 10.1021/jm970765q
36. Sugimori, M.; Ejima, A.; Ohsuki, S.; Uoto, K.; Mitsui, I.; Matsumoto, K.; Kawato, Y.; Yasuoka, M.; Sato, K.; Tagawa, H. et al. Antitumor agents. 7. Synthesis and antitumor activity of novel hexacyclic camptothecin analogues J. Med. Chem. 1994, 37 (19) 3033-9 10.1021/jm00045a007
37. Leu, Y. L.; Chen, C. S.; Wu, Y. J.; Chern, J. W. Benzyl ether-linked glucuronide derivative of 10-hydroxycamptothecin designed for selective camptothecin-based anticancer therapy J. Med. Chem. 2008, 51 (6) 1740-6 10.1021/jm701151c
38. Chu, Y. W.; Yang, P. C.; Yang, S. C.; Shyu, Y. C.; Hendrix, M. J.; Wu, R.; Wu, C. W. Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line Am. J. Respir. Cell Mol. Biol. 1997, 17 (3) 353-60 10.1165/ajrcmb.17.3.2837
39. Marshall, C. J.; Franks, L. M.; Carbonell, A. W. Markers of neoplastic transformation in epithelial cell lines derived from human carcinomas J. Natl. Cancer Inst 1977, 58 (6) 1743-51
40. Mi, Z.; Burke, T. G. Marked interspecies variations concerning the interactions of camptothecin with serum albumins: a frequency-domain fluorescence spectroscopic study Biochemistry 1994, 33 (42) 12540-5 10.1021/bi00208a002
41. Mürdter, T. E.; Friedel, G.; Backman, J. T.; McClellan, M.; Schick, M.; Gerken, M.; Bosslet, K.; Fritz, P.; Toomes, H.; Kroemer, H. K.; Sperker, B. Dose optimization of a doxorubicin prodrug (HMR 1826) in isolated perfused human lungs: low tumor pH promotes prodrug activation by beta-glucuronidase J. Pharmacol. Exp. Ther. 2002, 301 (1) 223-228 10.1124/jpet.301.1.223
42. Rivory, L. P. Metabolism of CPT-11. Impact on activity Ann. N. Y. Acad. Sci. 2000, 922, 205-15 10.1111/j.1749-6632.2000.tb07039.x
43. Roberts, A. B.; Wallace, B. D.; Venkatesh, M. K.; Mani, S.; Redinbo, M. R. Molecular Insights into Microbial β-Glucuronidase Inhibition to Abrogate CPT-11 Toxicity Mol. Pharmacol. 2013, 84 (2) 208-217 10.1124/mol.113.085852
44. Wallace, B. D.; Wang, H.; Lane, K. T.; Scott, J. E.; Orans, J.; Koo, J. S.; Venkatesh, M.; Jobin, C.; Yeh, L.-A.; Mani, S.; Redinbo, M. R. Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme Science (Washington, DC, U. S.) 2010, 330 (6005) 831-835 10.1126/science.1191175
45. Wallace, B. D.; Roberts, A. B.; Pollet, R. M.; Ingle, J. D.; Biernat, K. A.; Pellock, S. J.; Venkatesh, M. K.; Guthrie, L.; O'Neal, S. K.; Robinson, S. J.; Dollinger, M.; Figueroa, E.; McShane, S. R.; Cohen, R. D.; Jin, J.; Frye, S. V.; Zamboni, W. C.; Pepe-Ranney, C.; Mani, S.; Kelly, L.; Redinbo, M. R. Structure and Inhibition of Microbiome beta-Glucuronidases Essential to the Alleviation of Cancer Drug Toxicity Chem. Biol. 2015, 22 (9) 1238-49 10.1016/j.chembiol.2015.08.005